Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jun;99(6):706-13.
doi: 10.1007/s12185-014-1575-1. Epub 2014 Apr 10.

Cardiac T2* MRI assessment in patients with thalassaemia major and its effect on the preference of chelation therapy

Affiliations

Cardiac T2* MRI assessment in patients with thalassaemia major and its effect on the preference of chelation therapy

Arzu Akcay et al. Int J Hematol. 2014 Jun.

Abstract

The aim of the study is to assess the relationship between T2* magnetic resonance imaging (MRI) values and age, serum ferritin level, left ventricular ejection fraction (LVEF), splenectomy status, and to identify appropriate modifications to chelation therapy based on T2* MRI results of children with thalassaemia major. Sixty-four patients with thalassaemia major (37 girls/27 boys) older than 8 years of age were enrolled in the study. Based on the first T2* MRI, the patients' myocardial iron depositions were classified into three groups: T2* MRI <10 ms (high risk group), T2* MRI 10-20 ms (medium-risk group) and T2* MRI >20 ms (low-risk group). There was no significant relationship between T2* MRI value and ages, serum ferritin levels and splenectomy status of thalassaemia major patients. The mean LVEFs were 60, 75, and 72.5 % in the high-, medium-, and low-risk groups, respectively (P = 0.006). The mean cardiac iron concentrations calculated from the T2* MRI values were 4.96 ± 1.93, 1.65 ± 0.37, and 0.81 ± 0.27 mg/g in the high-, medium-, and low-risk groups, respectively. Chelation therapies were re-designed in 24 (37.5 %) patients according to cardiac risk as assessed by cardiac T2* MRI. In conclusion, until recently, T2* MRI has been employed to demonstrate cardiac siderosis without a direct relationship with the markers used in follow-up of patients with thalassaemia. However, modifications of chelation therapies could reliably be planned according to severity of iron load displayed by T2* MRI.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Hemoglobin. 2006;30(2):239-49 - PubMed
    1. Circulation. 2011 Apr 12;123(14):1519-28 - PubMed
    1. Circulation. 2009 Nov 17;120(20):1961-8 - PubMed
    1. Blood. 2010 Mar 25;115(12):2364-71 - PubMed
    1. Blood. 2006 May 1;107(9):3738-44 - PubMed

MeSH terms

LinkOut - more resources